About Catalio Capital Management
Catalio Capital Management is a venture capital firm founded in 2016. It is primarily based out of New York City, United States. As of Sep 2026, Catalio Capital Management is an active investor, having invested in 87 companies, with 13 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series B round of Evvy Overall, Catalio Capital Management portfolio has seen 6 unicorns, 14 IPOs and 10 acquisitions including key companies like Recursion Pharmaceuticals, Abcellera Biologics and Neumora. A lot of funds co-invest with Catalio Capital Management, with names like Alexandria sharing a substantial percentage of its portfolio. Catalio Capital Management has team of 90 people including 9 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series A & 8 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Unicorns
Portfolio Soonicorns
Deals in last 12 months
Catalio Capital Management's List of Top Investments
Catalio Capital Management has a portfolio of 87 companies, including 6 unicorns. Their most notable investments are in RefleXion and Sensei Biotherapeutics.Their portfolio spans across United States, Switzerland, Israel and 4 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 3 other sectors, across stages such as Series B, Series A and 8 more. Here is the list of top investments by Catalio Capital Management:AI-enabled drug discovery and development platform for novel therapeutics. It focuses on identifying new targets and designing optimized molecules. The platform utilizes biological and chemical datasets, machine learning models, and a supercomputer to accelerate the discovery of medicines. It aims to improve the speed and efficiency of drug development for conditions with high unmet needs, including cancers and rare diseases. The company also forms strategic partnerships to expand its impact on patients.
Key facts about Recursion Pharmaceuticals
- Founded Year: 2013
- Location: New York (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $452M
- Employee Count: 755 as on Mar 31, 2026
- Investors: HTIF, Baillie Gifford and 47 Others
- Latest Funding Round: Post IPO, Jul 12, 2023, $*****
- Highlight: Public
AI-enabled platform for antibodies discovery. The company has developed Celium which is an antibody visualization software and suite of proprietary microfluidic single-cell assays used for antibody screening. The company uses its proprietary repertoire sequencing technologies with functional data from single B cells to annotate immune repertoires. It has also developed its proprietary humanized mouse platform for the development of humanized antibodies.
Key facts about Abcellera Biologics
- Founded Year: 2012
- Location: Vancouver (Canada)
- Annual Revenue: $50M - $100M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $115M
- Employee Count: 588 as on Aug 31, 2026
- Investors: HTIF, Benson Family Private Equity and 16 Others
- Latest Funding Round: Post IPO, Jun 10, 2021, $*****
- Highlight: Public
3. RefleXion
Provider of biology-guided radiotherapy system. Its patented technology leverages Positron Emission Tomography (PET) which allows tumors to continuously signal their location during treatment and guides personalized radiation therapy. The technology has applications in the treatment of Lung, prostate, and Breast cancers.
Key facts about RefleXion
- Founded Year: 2009
- Location: Hayward (United States)
- Valuation: $*****
- Stage: Series F
- Total Funding till date: $542M
- Employee Count: 123 as on Aug 31, 2026
- Investors: T. Rowe Price, GT Healthcare Capital Partners and 24 Others
- Latest Funding Round: Series F, Nov 13, 2023, $*****
- Highlight: Editors' Pick
Imbria Pharmaceuticals provides therapeutics solution by translation the cellular metabolism. It is involved in providing transformative medicine, by altering the cellular metabolism and mitochondrial function.
Key facts about Imbria Pharmaceuticals
- Founded Year: 2014
- Location: Boston (United States)
- Stage: Series B
- Total Funding till date: $157M
- Investors: RA Capital Management, Deep Track Capital and 6 Others
- Latest Funding Round: Series B, Nov 17, 2025, $*****
- Highlight: Editors' Pick
5. 9amHealth
Provider of whole-body approach to healthcare delivering multiple services. The company's services include personalized care plans, prescription medication, at-home lab tests, virtual medical care, devices & supplies.
Key facts about 9amHealth
- Founded Year: 2021
- Location: Encinitas (United States)
- Stage: Series B
- Total Funding till date: $55.8M
- Employee Count: 196 as on Aug 31, 2026
- Investors: Bayer, Cigna Ventures and 10 Others
- Latest Funding Round: Series B, Mar 16, 2026, $*****
- Highlight: Editors' Pick
Catalio Capital Management's Year-on-Year Investment Trends
Catalio Capital Management has invested in 87 companies over the last 7 years, with an average of 12 new investments annually in the last 5 years. In 2025, it made 15 investments, while as of Sep 2026, it has made 12 investments in this year. Its most recent first time investment was in Evvy and most recent follow-on round was in Superluminal Medicines.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 9 | 3 | 12 |
2025 | 10 | 5 | 15 |
2024 | 12 | 4 | 16 |
2023 | 10 | 8 | 18 |
2022 | 18 | 2 | 20 |
2021 | 13 | 1 | 14 |
2020 | 6 | 0 | 6 |
2019 | 1 | 0 | 1 |
Catalio Capital Management's Investments by Stage
Catalio Capital Management has made 23 investments in Series B stage with an average round size of $78.7M, 22 investments in Series A stage with an average round size of $85M and 11 investments in Series C stage with an average round size of $124M.Stage of entry | No. of Investments |
|---|---|
Series B | 23 |
Series A | 22 |
Series C | 11 |
Series D | 8 |
Series E | 5 |
Others | 10 |
Note: We have considered here, only first round of investments
Catalio Capital Management's Investments by Sector
Catalio Capital Management has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Enterprise Applications and Healthcare. Notably, it has invested in 79 Tech companies, 76 Enterprise (B2B) companies, 15 Software companies and at least 10 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 64 |
High Tech | 21 |
HealthTech | 20 |
Enterprise Applications | 13 |
Healthcare | 6 |
Others | 13 |
Note: We have considered here, only first round of investments
Catalio Capital Management's Investments by Geography
Catalio Capital Management has made most investments in United States (70), followed by Switzerland where it has made 3 investments.Country | No. of Investments |
|---|---|
United States | 70 |
Switzerland | 3 |
Israel | 2 |
United Kingdom | 2 |
Australia | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Catalio Capital Management's recent investments
Catalio Capital Management has made 12 investments in 2026 so far. Evvy and Superluminal Medicines are the latest among them.Here are the most recent investments by Catalio Capital Management:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 15, 2026 | United States | Series B | 4222 | [+10] | |
Aug 10, 2026 | United States | Series B | 2279 | [+8] | |
Jul 28, 2026 | United States | Series B | 1966 | [+7] | |
Jul 16, 2026 | United States | Series C | 3317 | ||
Jun 30, 2026 | Australia | Series D | 2684 | [+17] |
Unicorns in Catalio Capital Management's Portfolio
Catalio Capital Management has 6 unicorns in its portfolio - Lila Sciences, Enveda, Visby Medical and others. The most recent unicorn in their portfolio is Lila Sciences. It became a unicorn in 2025.Here is a list of unicorns in Catalio Capital Management's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
65 | Developer of AI-powered autonomous scientific research platforms | 2023 | Cambridge | Series A | ldzpznx | ||
63 | AI-based platform to decipher the chemistry of nature and develop new medicines | 2019 | Boulder | Series D | xsafazm | ||
62 | Provider of at-home tests for sexually transmitted infections with telehealth | 2010 | San Jose | Series F | booaegm | ||
66 | Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | - | Series E | {dwenog | ||
65 | Developer of next-generation of immunomodulatory therapeutics | 2018 | - | Series B | ervqkvs |
IPOs and Publicly Listed companies in Catalio Capital Management's Portfolio
14 of Catalio Capital Management's portfolio companies have become public. Parabilis Medicines got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jun 2026 at marketcap of $2.33B and Odyssey got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $849M.Here are Catalio Capital Management's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 10, 2026 | Mar 01, 2024 | Series E | 8303 | |
May 08, 2026 | Oct 13, 2022 | Series B | 6717 | |
Apr 30, 2026 | Sep 27, 2023 | Series C | 7292 | |
Oct 25, 2024 | Jan 27, 2022 | Series A | 4450 | |
Feb 09, 2024 | Dec 20, 2022 | Series B | 4477 |
Acquired companies in Catalio Capital Management's Portfolio
10 companies from Catalio Capital Management's portfolio have been acquired. The most recent acquisition was Perfuse Therapeutics in May 2026 by Bayer for $*****.Here are Catalio Capital Management's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 06, 2026 | - | - | 7498 | |
Aug 22, 2025 | Mar 09, 2021 | Series C | 1331 | |
Dec 23, 2024 | - | - | 3062 | |
Dec 19, 2024 | Mar 08, 2022 | Series B | 9399 | |
Jun 27, 2024 | Mar 24, 2022 | Series B | 5645 |
Team profile of Catalio Capital Management
Catalio Capital Management has a team of 90 members including 9 Partners, 49 Venture Partners and 7 Principals located in United States and United Kingdom. Catalio Capital Management's team sits on the board of 1 company.Here is a list of top team members in Catalio Capital Management:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | - | - | ||
Partner | New York City | - | ||
Partner | Bethesda | - | ||
Partner | New York City | - | ||
Partner | Baltimore | - | ||
Partner | New York City | - | ||
Partner | New York | - | ||
Partner | New York City | - | - | |
Partner | New York | - | ||
Venture Partner | Weston | - | - |
Co-investors of Catalio Capital Management
Over the past 7 years, 792 investors have co-invested in Catalio Capital Management's portfolio companies. This includes funds and angels.
- Invested before Catalio Capital Management: HHS, RA Capital Management and 308 others have invested in rounds before Catalio Capital Management. There are 6 companies where HHS has invested before Catalio Capital Management and 6 companies where RA Capital Management has invested before Catalio Capital Management.
- Top Co-investors of Catalio Capital Management: 297 investors entered a company along with Catalio Capital Management. These include investors like Alexandria (10 companies).
- Invested after Catalio Capital Management: A total of 185 investors have invested in Catalio Capital Management's portfolio after their investments. Top Investors include Alexandria (3 companies), Kinnevik (2 companies) and Nvidia (2 companies).
Recent News related to Catalio Capital Management
•
•
Superluminal Medicines Secures $60 Million for Rare Obesity Therapy DevelopmentPharmaceutical Business Review•Sep 04, 2026•Deep Track Capital, Insight Partners, Nvidia, Cooley and 9 others
•
Claris collects $118M to take eye drop into pivotal testing next year - Endpoints NewsGoogle•Jul 28, 2026•Claris Bio, Sofinnova Investments, Novo Holdings, Aisling Capital and 5 others
•
Flourish Raises $500M to Reinvent AI EfficiencyVentureburn•Jun 05, 2026•Catalio Capital Management, Flourish, Google Ventures, Lux Capital
•
Lila Sciences Raises $350M in Series A FundingFinSMEs•Jun 04, 2026•Lila Sciences, Braidwell, Catalio Capital Management
•
9amHealth Raises $26M to Expand AI-Driven Virtual Specialty Care for Chronic ConditionsHIT Consultant•May 13, 2026•Define Ventures, 9amHealth, Catalio Capital Management, SemperVirens and 1 other
•
Catalio Capital Management Invests in ProSomnus Sleep TechnologiesMedical Product Outsourcing•Apr 13, 2026•Catalio Capital Management
•
Imperative Care Raises $100M in FundingFinSMEs•Mar 18, 2026•Patient Square Capital, Imperative Care, Bain Capital Life Sciences, Perceptive Advisors and 7 others
•
•
ProSomnus Receives $38M in Strategic InvestmentFinSMEs•Feb 19, 2026•Catalio Capital Management, ProSomnus
